Analysts Expect Apricus Biosciences Inc (APRI) to Post -$0.13 Earnings Per Share

Equities research analysts expect Apricus Biosciences Inc (NASDAQ:APRI) to announce earnings per share of ($0.13) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Apricus Biosciences’ earnings. Apricus Biosciences posted earnings of ($0.04) per share in the same quarter last year, which indicates a negative year over year growth rate of 225%. The firm is scheduled to report its next earnings results on Monday, March 12th.

On average, analysts expect that Apricus Biosciences will report full year earnings of ($0.60) per share for the current year, with EPS estimates ranging from ($0.92) to ($0.28). For the next year, analysts anticipate that the business will report earnings of $1.28 per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for Apricus Biosciences.

Apricus Biosciences (NASDAQ:APRI) last posted its earnings results on Thursday, November 2nd. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.15). During the same quarter last year, the firm earned ($0.19) EPS.

A number of research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $4.50 price objective on shares of Apricus Biosciences in a research report on Friday, November 3rd. Zacks Investment Research raised shares of Apricus Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research report on Tuesday, October 31st.

Apricus Biosciences (APRI) remained flat at $$1.82 during midday trading on Wednesday. 305,329 shares of the stock were exchanged, compared to its average volume of 147,494. The firm has a market cap of $27.68, a PE ratio of 3.14 and a beta of 0.44. Apricus Biosciences has a 1-year low of $0.86 and a 1-year high of $4.07.

COPYRIGHT VIOLATION NOTICE: “Analysts Expect Apricus Biosciences Inc (APRI) to Post -$0.13 Earnings Per Share” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Get a free copy of the Zacks research report on Apricus Biosciences (APRI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit